Johnson & Johnson Bets $785 Million on In Vivo CAR-T, Securing Exclusive Option to Acquire Sail

If CAR-T could eliminate the lengthy process of extracting cells, sending them to a facility for modification, and then reinfusing them into the patient, it could change not only how cell therapies are manufactured but also the range of diseases they can reach. Johnson & Johnson has now brought this still-preclinical concept into its immunology strategy through a sizable collaboration.

Johnson & Johnson announced a collaboration with Sail Biomedicines to advance the latter’s lead in vivo CAR-T program and platform technology for immune-mediated diseases, with the potential to expand into other therapeutic targets in the future. The deal includes upfront payments totaling $785 million, of which $465 million is an equity investment; Sail may receive an additional $140 million upon achieving certain development milestones.

The agreement also grants Johnson & Johnson an exclusive option to acquire Sail. If it decides to exercise the option, Johnson & Johnson will pay an additional $2.58 billion; together with the upfront and milestone payments, the total potential payments could reach $3.505 billion. However, this is not a confirmed acquisition, and the transaction would remain subject to regulatory review and other closing conditions.

Traditional CAR-T typically involves collecting T cells from a patient, genetically engineering and expanding them outside the body, and then sending them back to the hospital for infusion. Sail’s approach instead directly reprograms immune cells inside the body to turn them into CAR-T cells with specific recognition capabilities, with the aim of creating a treatment model that can be supplied at greater scale. In autoimmune diseases, the central concept is to eliminate or reset the immune cells driving the disease, giving the dysregulated immune system an opportunity to reestablish itself.

For Johnson & Johnson, the agreement extends its existing oncology CAR-T experience into immunology while preserving the flexibility to collaborate first and later decide whether to acquire the entire company. The company estimates that, if the option is exercised, the related agreement will reduce adjusted earnings per share by approximately $0.18 in 2026 and approximately $1.28 in 2027, indicating that the financial investment required to gain access to the platform extends beyond early-stage research funding.

However, publicly available information remains quite limited: Johnson & Johnson has not disclosed the specific disease targeted by the lead program, the CAR target, the delivery method, or the clinical development timeline, and no human safety or efficacy data are available. In vivo reprogramming must also address whether delivery is sufficiently precise, whether CAR-T cells can be controlled at an appropriate dose and for an appropriate duration, and issues such as unintended tissue exposure. What this deal demonstrates first is that a major pharmaceutical company is willing to pay a high price for access to the technology; it does not yet demonstrate that in vivo CAR-T has crossed the threshold of clinical feasibility.